24 weeks of interferon-ribavirin therapy should not routinely be given to all hepatitis C patients.
DJ van Leeuwen;
Leland J Yee;
Rebecca G Langner;
(2002)
24 weeks of interferon-ribavirin therapy should not routinely be given to all hepatitis C patients.
The American journal of gastroenterology, 97 (2).
pp. 497-498.
ISSN 0002-9270
DOI: 10.1111/j.1572-0241.2002.05512.x
| Item Type | Article |
|---|---|
| Keywords | Antiviral Agents/*administration & dosage, Drug Administration Schedule, Drug Therapy, Combination, Female, Follow-Up Studies, Hepatitis C, Chronic/diagnosis/*drug therapy, Human, Interferon-alpha/*administration & dosage, Male, Prospective Studies, Ribavirin/*administration & dosage, Risk Assessment, Sensitivity and Specificity, Time Factors, Treatment Outcome, *Viral Load, Antiviral Agents, administration & dosage, Drug Administration Schedule, Drug Therapy, Combination, Female, Follow-Up Studies, Hepatitis C, Chronic, diagnosis, drug therapy, Human, Interferon-alpha, administration & dosage, Male, Prospective Studies, Ribavirin, administration & dosage, Risk Assessment, Sensitivity and Specificity, Time Factors, Treatment Outcome, Viral Load |
| ISI | 173880400050 |